Article
Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.
The Journal of antimicrobial chemotherapy - 1 Oct 2006
Ellington Matthew J, Livermore David M, Pitt Tyrone L, Hall Lucinda M C, Woodford Neil
Abstract excerpt
OBJECTIVES: Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum beta-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.